Navigation Links
ABAXIS Announces Worldwide Animal Health Licensing Agreement for Rapid Test Technology
Date:1/7/2009

UNION CITY, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Abaxis, Inc. (Nasdaq: ABAX), a medical products company manufacturing point-of-care blood analysis instruments for both the medical and veterinary markets, announced today that it has entered into a license agreement for co-exclusive worldwide rights in the field of animal health diagnostics in the professional marketplace for certain technologies pertaining to lateral flow immunoassay devices and methods.

This license agreement provides Abaxis the co-exclusive opportunity to utilize these technologies to expand the Abaxis product portfolio and enter on a large scale the professional veterinary rapid diagnostic market. This includes point of care tests for infectious diseases, hormones and therapeutic drugs. The total market for these types of tests in the animal health and laboratory animal research is estimated to be over $100,000,000 in the United States alone.

"The VetScan brand is recognized in the research market and animal health industry worldwide as synonymous with quality, reliability and unparalleled cost effectiveness. The Abaxis rapid diagnostic product line now in development will extend these attributes into rapid test lateral flow devices and maintain Abaxis' standards of product excellence," said Clint Severson, Chairman and Chief Executive Officer. Kenneth Aron, PhD, Chief Technology Officer added, "With this license agreement we will now be able to develop and offer point of care tests for animal health in the professional marketplace in both our rotor format and in the popular "strip test" format. Having this license means that we can now move forward with an aggressive plan to develop and place our product offerings in the widest range of professional market segments throughout the veterinary industry."

About Abaxis, Inc.

Abaxi
'/>"/>

SOURCE Abaxis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Abaxis, Inc. to Present at the RBC Capital Markets 2008 Healthcare Conference
2. Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009
3. Abaxis, Inc. to Present at the Sidoti & Companys Seventh Annual West Coast Emerging Growth Institutional Investor Forum
4. Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009
5. Abaxis to Report Third Quarter Fiscal 2008 Financial Results Thursday, January 31, 2008
6. Abaxis CEO Clint Severson Named Entrepreneur of the Year by Forbes Magazine
7. Abaxis to Present at the Sidoti & Company Sixth Annual San Francisco Institutional Investor Forum Conference
8. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
9. Horizon Therapeutics Announces Senior Management Appointments
10. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
11. Star Scientific Announces Successful Completion of Product Satisfaction Study - Results Show Potential for Development and Manufacturing of New Pharmaceutical Product for Smoking and Smokeless Tobacco Cessation

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...RNewswire-FirstCall/ -- Omeros Corporation (Nasdaq...lts for the third quarter ended September 30, 2009...meros reported a net loss of $3.9 million, or $1.3...lion, or $2.54 per share, for the same period in 2... the Company reported a net loss of $15.5 million,...
(Date:11/19/2009)...A, Md., Nov. 19 Spherix ...technology for diabetes therapy, and a provider of...ood, supplement, biotechnology and pharmaceutical ...y reported $6.3 million registered direct placemen...f its common stock and warrants to purchase up to ...
(Date:11/19/2009)... 19 Spherix Incorporated...or diabetes therapy, and a provider of technical a...ent, biotechnology and pharmaceutical companies, t...ting of Shareholders. ,, At the meeting, shareh...ected the following members to the Board of Direct...
(Date:11/19/2009)...many, November 19 MONITORING FORCE...6th, 2009 Flibanserin in the,indication treatment-...s,disease for orphan drug status designation with ...uced dyskinesia is a complication of the mainstay,...rden to some of those,affected, since it may be di...
Breaking Biology Technology:Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2
...ences, Inc. (Nasdaq: SGMO ), the world leader in...inding proteins (ZFPs), announced today that it ha...ons grant from the Bill & Melinda Gates Founda... health research project conducted by Sangamo scie...ivo Treatment of HIV Infection." , , Sangamo,s p...
...n, an orthopedic implants company focused on silic...hat it has received a CE (Conformite Europeene) ma...ral spacers using novel CSC (cancellous-structured...ing Amedica,s novel silicon nitride ceramic, offer...d to promote bony fusion. , , The Valeo family ...
...accine is available now for testing worldwide, fro...cine based on the same Replikins peptide technolog...year ago that the current H1N1 outbreak/pandemic w...unique advantage of the Replikins vaccine is its r...ated that conventionally developed H1N1 vaccines w...
Other Biology Technology:Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research 2Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research 3Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research 4Amedica Receives CE Mark for Valeo(TM) Ceramic Spinal Implant System Incorporating CSC Technology 2First H1N1 Swine Flu Vaccine, Replikins-Based, Is Ready Now for Testing Worldwide 2
(Date:11/20/2009)...p of University of Oklahoma researchers were seque...man genome project. Today, the OU Advanced Cente...rnational effort to sequence the tomato genome wit...ence Foundation for plant genomics. , "The toma...ving the tomato and crop yields will improve quali...
(Date:11/20/2009)..., November 19, 2009 The estimated 4.6 million Ame...isk of developing respiratory symptoms due to poor...onnaire study undertaken earlier this year by inve... Veterinary Medicine. , The studywhich polled mo...t 50 percent of individuals working in barns compl...
(Date:11/20/2009)...ilable in German . , In the current online ...Dr. Stefanie Eyerich and Dr. Kilian Eyerich togeth...don and Istituto Dermopatico dell,Immacolata in Ro...resents a milestone on the way to developing new t...ch as psoriasis and allergic reactions and potenti...
Breaking Biology News(10 mins):NSF awards $7.5M grant to University of Oklahoma for plant genomics 2Barn personnel experience higher-than-average rates of respiratory symptoms 2Discovery of new type of immune cells regulating inflammation in chronic diseases 2Plainview Milk Products Cooperative Institutes New Policies and Procedures 51367 1Plainview Milk Products Cooperative Institutes New Policies and Procedures 51367 2Pioneer Surgical Technology Inc Names Thomas J McLeer as Chief Marketing Officer and General Manager of Spinal Operations 51364 1Pioneer Surgical Technology Inc Names Thomas J McLeer as Chief Marketing Officer and General Manager of Spinal Operations 51364 2Blue Cross and Blue Shield of Illinois Urges Constant Vigilance Against Growing Threat of Killer Superbug 51361 1Blue Cross and Blue Shield of Illinois Urges Constant Vigilance Against Growing Threat of Killer Superbug 51361 2Blue Cross and Blue Shield of Illinois Urges Constant Vigilance Against Growing Threat of Killer Superbug 51361 3
...URHAM, N.H. Stacia Sower, professor of biochemist...mparative Endocrinology at the University of New H...ational Science Foundation (NSF) for research on b...h the four-year grant, Sower will build upon her d...monal genomics and proteomics. Sower defines the p...
...hen a single female is nearby, female antbirds wil... apparent attempt to keep their messages from gett...nline on March 12th in Current Biology , a Cell P...on by singing a different tune. , The findings of...and "jamming avoidance" occur between mates, accor...
...IRMINGHAM, Ala. -- University of Alabama at Birmin...ive a top international award in nephrology, the L...ment in the Understanding of Polycystic Kidney Dis...rnational Society of Nephrology. , She was cited ...ycystic kidney disease (PKD) research, clinical pr...
Other Biology News:Major NSF grant boosts UNH research on hormonal genomics 2Female birds 'jam' their mates' flirtatious songs 2UAB's Lisa Guay-Woodford earns top international nephrology prize 2UAB's Lisa Guay-Woodford earns top international nephrology prize 3
acridine orange 10-nonyl bromide (nonyl acridine orange) from Molecular Probes (Invitrogen)
Rabbit Anti-dansyl Polyclonal Antibody, Unconjugated from Molecular Probes (Invitrogen)
propidium iodide *FluoroPure™ grade* from Molecular Probes (Invitrogen)
Mouse Anti-Rat RT1Ac (Class I Polymorphic) Monoclonal Antibody, Unconjugated from AbD Serotec
Biology Products: